Jazz Pharmaceuticals plc diskutieren
Jazz Pharmaceuticals plc
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Aktie / Pharmazeutika / Mid Cap /
99,66 €
-0,20 %
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Piper Sandler from $171.00 to $188.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $200.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $190.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $222.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Barclays PLC from $230.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $169.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $222.00 to $210.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $208.00 to $205.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Royal Bank of Canada from $175.00 to $174.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Piper Sandler from $188.00 to $166.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at JPMorgan Chase & Co. from $190.00 to $202.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Neueste Beiträge
StockNews_com in Quaker Chemical Corp. diskutieren